Sociedad Americana de Hirudoterapia

The Use of Medicinal Leeching in Breast Surgery: A Systematic Review

Rajaram R, Cevik J, Bhindi N, Seth I, Rozen WM (2024) · Journal of Clinical Medicine · n=28

Detalle de evidencia de RCTReferencia del ensayo
GRADE bajaCohorte / serie de casosCondición: Breast Reconstruction Flap Salvage →
Tamaño de muestra de este ensayo en comparación con otros ensayos de Breast Reconstruction Flap SalvageRajaram R 202428Maetz B 20122Freeman M 20151Moffat AD 20151Torresetti M 20241Baccarani A 20221
Este ensayo (destacado) por tamaño de muestra junto a otros ensayos indexados de Breast Reconstruction Flap Salvage. Los ensayos más grandes generalmente tienen mayor peso estadístico.

Perfil del estudio

Diseño
PRISMA-compliant systematic review of medicinal-leech therapy in breast surgery (PubMed + Embase inception to November 2023); Peninsula Health Plastic Surgery, Monash University, Australia
Tamaño de la muestra (n)
28
Intervención
Whole-leech Hirudo medicinalis therapy for venous congestion in breast surgery (reconstructive and non-reconstructive: DIEP, TRAM, mastopexy, mammoplasty)
Comparador
No comparator — descriptive synthesis across heterogeneous case series and case reports
Punto final primario
Tissue-transfer salvage rate and complication rate of medicinal leeching in breast surgery
Resultado primario
18 studies (4 case series + 14 case reports), 28 patients pooled; 75% of patients underwent reconstructive surgery; median 2 leeches per session, 3 sessions per day, 3 days of leeching; 75% of all tissue transfers salvaged; complication rate 81.1% (mostly infection and anaemia)
Duración del seguimiento
Variable across included studies (acute postoperative to 6 months)

Hallazgos clave

  • 75% tissue-transfer salvage rate across pooled breast-surgery leech cases
  • Median dosing pattern: 2 leeches per session, 3 sessions per day, 3 days total
  • High complication rate (81.1%) dominated by infection and anaemia
  • 75% of cases were reconstructive (DIEP, TRAM); 25% non-reconstructive (mammoplasty, mastopexy)
  • Provides first systematically pooled efficacy estimate for K040187 indication subset (breast)

Limitaciones

  • Predominantly case reports and small case series — high risk of publication bias toward salvage successes
  • Only 28 patients across 18 studies — limits subgroup analysis
  • Heterogeneity in leech dosing, antibiotic prophylaxis, and transfusion thresholds
  • Complication rate not adjusted for severity (mild anaemia counted alongside transfusion-requiring)
  • No control or non-leech salvage comparator

Implicaciones clínicas

Rajaram 2024 is the most current evidence synthesis for the K040187 device indication subset of breast surgery (DIEP, TRAM, mammoplasty, mastopexy). For US clinicians, the 75% salvage rate is consistent with the broader microsurgical leech literature (Whitaker 2011, Lehnhardt 2021) and supports continued use in selected venous-congestion scenarios. The 81.1% complication rate underscores the need for proactive Aeromonas-active prophylaxis, hemoglobin monitoring, and clear transfusion-threshold protocols. The findings reinforce ASH's recommendation that breast-flap leech therapy be performed in centers with established protocols and rapid microsurgical revision capability.

Estudios relacionados

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.